LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

LLY

1,018.6

+0.41%↑

JNJ

195.64

+0.3%↑

ABBV

236.99

+1.61%↑

UNH

332.8

-2.01%↓

AZN

88.87

+0.69%↑

Search

Simulations Plus Inc

Открыт

СекторЗдравоохранение

17.04 -1.79

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

16.91

Макс.

17.43

Ключевые показатели

By Trading Economics

Доход

-70M

-67M

Продажи

-2.1M

20M

P/E

Средняя по отрасли

48.528

105.69

Дивидендная доходность

0.48

Рентабельность продаж

-330.585

Сотрудники

243

EBITDA

327K

5.3M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

-7.67% downside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

0.48%

2.37%

Следующий отчет о доходах

1 дек. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-5.6M

346M

Предыдущая цена открытия

18.83

Предыдущая цена закрытия

17.04

Новостные настроения

By Acuity

50%

50%

182 / 374 Рейтинг в Healthcare

Simulations Plus Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 нояб. 2025 г., 21:55 UTC

Отчет

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

12 нояб. 2025 г., 21:34 UTC

Отчет

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

12 нояб. 2025 г., 23:44 UTC

Обсуждения рынка

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

12 нояб. 2025 г., 23:38 UTC

Обсуждения рынка

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

12 нояб. 2025 г., 23:13 UTC

Отчет

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

12 нояб. 2025 г., 23:13 UTC

Отчет

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

12 нояб. 2025 г., 23:13 UTC

Отчет

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

12 нояб. 2025 г., 23:13 UTC

Отчет

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

12 нояб. 2025 г., 22:30 UTC

Обсуждения рынка
Отчет

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

12 нояб. 2025 г., 22:18 UTC

Отчет

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

12 нояб. 2025 г., 22:12 UTC

Обсуждения рынка

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

12 нояб. 2025 г., 22:05 UTC

Отчет

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

12 нояб. 2025 г., 22:04 UTC

Отчет

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

12 нояб. 2025 г., 22:04 UTC

Отчет

Pan American Silver 3Q Adj EPS 48c >PAAS

12 нояб. 2025 г., 22:04 UTC

Отчет

Pan American Silver 3Q Rev $884.4M >PAAS

12 нояб. 2025 г., 22:04 UTC

Отчет

Pan American Silver 3Q EPS 45c >PAAS

12 нояб. 2025 г., 22:03 UTC

Отчет

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

12 нояб. 2025 г., 22:02 UTC

Отчет

Manulife Financial 3Q Net C$1.8B >MFC

12 нояб. 2025 г., 22:02 UTC

Отчет

Manulife Financial 3Q Adj EPS C$1.16 >MFC

12 нояб. 2025 г., 22:02 UTC

Отчет

Manulife Financial 3Q EPS C$1.02 >MFC

12 нояб. 2025 г., 21:53 UTC

Приобретения, слияния, поглощения

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

12 нояб. 2025 г., 21:53 UTC

Приобретения, слияния, поглощения

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

12 нояб. 2025 г., 21:53 UTC

Приобретения, слияния, поглощения

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

12 нояб. 2025 г., 21:53 UTC

Приобретения, слияния, поглощения

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

12 нояб. 2025 г., 21:52 UTC

Приобретения, слияния, поглощения

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

12 нояб. 2025 г., 21:51 UTC

Приобретения, слияния, поглощения

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

12 нояб. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет

Basic Materials Roundup: Market Talk

12 нояб. 2025 г., 21:49 UTC

Отчет

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

12 нояб. 2025 г., 21:48 UTC

Отчет

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

12 нояб. 2025 г., 21:40 UTC

Отчет

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

Сравнение c конкурентами

Изменение цены

Simulations Plus Inc Прогноз

Целевая цена

By TipRanks

-7.67% падение

Прогноз на 12 месяцев

Средняя 16 USD  -7.67%

Максимум 16 USD

Минимум 16 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Simulations Plus Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

4 ratings

2

Покупка

2

Удержание

0

Продажа

Настроения

By Acuity

182 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat